22 research outputs found
Review article: vaccination for patients with inflammatory bowel disease during the COVID-19 pandemic
Background: Poor immune responses are frequently observed in patients with inflammatory bowel disease (IBD) receiving established vaccines; risk factors include
immunosuppressants and active disease. Aims: To summarise available information regarding immune responses achieved in patients with IBD receiving established vaccines. Using this information, to identify risk factors in the IBD population related to poor vaccine-induced immunity that may be applicable to vaccines against COVID-19.
Methods: We undertook a literature review on immunity to currently recommended
vaccines for patients with IBD and to COVID-19 vaccines and summarised the relevant literature. Results: Patients with IBD have reduced immune responses following vaccination compared to the general population. Factors including the use of immunomodulators and anti-TNF agents reduce response rates. Patients with IBD should be vaccinated against COVID-19 at the earliest opportunity as recommended by International Advisory Committees, and vaccination should not be deferred because a patient is receiving immune-modifying therapies. Antibody titres to COVID-19 vaccines appear to be reduced in patients receiving anti-TNF therapy, especially in combination
with immunomodulators after one vaccination. Therefore, we should optimise any
established risk factors that could impact response to vaccination in patients with IBD before vaccination. Conclusions: Ideally, patients with IBD should be vaccinated at the earliest opportunity against COVID-19. Patients should be in remission and, if possible, have their corticosteroid dose minimised before vaccination. Further research is required to determine the impact of different biologics on vaccine response to COVID-19 and the
potential for booster vaccines or heterologous prime-boost vaccinations in the IBD
populatio
DNA Methylation Profiling in Inflammatory Bowel Disease Provides New Insights into Disease Pathogenesis.
Inflammatory bowel diseases (IBDs) are heterogeneous disorders with complex aetiology. Quantitative genetic studies suggest that only a small proportion of the disease variance observed in IBD is accounted for by genetic variation, indicating a potential role for differential epigenetic regulation in disease aetiology. The aim of this study was to assess genome-wide DNA methylation changes specifically associated with ulcerative colitis (UC), Crohn's disease (CD) and IBD activity.This article is freely available via Open Access. Click on the ‘Additional Link’ above to access the full-text from the publisher’s site.P30 DK56338/DK/NIDDK NIH HHS/United State
Souvenirs de la Flandre-wallonne : recherches historiques et choix de documents relatifs à Douai et à la province / publiés par une réunion d'amateurs et d'archéologues
18711871 (T11)-1871.Appartient à l’ensemble documentaire : NordPdeC1Appartient à l’ensemble documentaire : RfnEns0Appartient à l’ensemble documentaire : RfnEuro1Appartient à l’ensemble documentaire : RfnCoop
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management.
This paper is the first in a series of two publications relating to the European Crohn's and Colitis Organisation [ECCO] evidence-based consensus on the diagnosis and management of Crohn's disease and concerns the methodology of the consensus process, and the classification, diagnosis and medical management of active and quiescent Crohn's disease. Surgical management as well as special situations including management of perianal Crohn's disease of this ECCO Consensus are covered in a subsequent second paper [Gionchetti et al JCC 2016]